Hims & Hers: Sharp Correction After the end of the FDA Exception and Cigna Offensive
Reading Time: 2 minutes
Regulatory changes and new pricing strategies are slowing down the rise of the telemedicine stock Competition from insurers is increasing After a strong run on the stock of the telemedicine provider Hims & Hers Health (Ticker: HIMS), which has been fueled since the beginning of the year by growth fantasies surrounding digital healthcare and GLP-1 medications as well as an extremely high short-seller ratio, a sharp correction is now in sight. On May 21, 2025, the stock of Hims & Hers Health (Ticker: HIMS) saw a significant decline,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
